What is RLYB's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.09B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for RLYB?

P/E (TTM) is 1.98 and 52-week range is $3.67 to $17.57 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s RLYB figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for RLYB?

The company profile lists revenue (TTM) near $590K, net income (TTM) near $-538M, EPS (TTM) near $7.89 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Rallybio Corp based, and what identifiers does Chartloom list?

The company context section lists headquarters in New Haven, Connecticut, US, 5.3M shares outstanding, ISIN US75120L2097 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Rallybio Corp

$RLYB

Health Care · Biotechnology

IR Run Scenarios

$17.02

+0.18%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Rallybio Corp. engages in the identification, research and development, and manufacture of clinical biotechnology products and therapies for severe and rare diseases. The company is headquartered in New Haven, Connecticut and currently employs 14 full-time employees. The company went IPO on 2021-07-29. The company has a pipeline of product candidates aimed at addressing diseases with unmet medical need in the areas of complement dysregulation and hematology. The Company’s lead program, RLYB116, is a differentiated C5 inhibitor with the potential to treat diseases of complement dysregulation, with an initial focus on immune platelet transfusion refractoriness (PTR) and refractory antiphospholipid syndrome (APS). RLYB116 is a novel, once-weekly, small volume, subcutaneously injected C5 inhibitor designed to meet patient demand for a convenient, self-administered at-home solution. Its pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload. Its RLYB114 is a pegylated C5 inhibitor in development for complement-mediated ophthalmic disorders.

Employees

Website

rallybio.com/

IPO

2021-07-29

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)